Get the Stockscreener App
33.40
3.76%
0.935
Inhibrx Biosciences Inc stock is traded at $33.40, with a volume of 53,913.
It is up +3.76% in the last 24 hours and up +22.40% over the past month.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
See More
Previous Close:
$32.47
Open:
$32.69
24h Volume:
53,913
Relative Volume:
0.44
Market Cap:
$486.41M
Revenue:
$1.80M
Net Income/Loss:
$1.76B
P/E Ratio:
0.2814
EPS:
118.674
Net Cash Flow:
$-149.23M
1W Performance:
-3.65%
1M Performance:
+22.40%
6M Performance:
+190.14%
1Y Performance:
+115.38%
1-Day Range:
$32.36
$34.55
1-Week Range:
$31.28
$35.96
52-Week Range:
$10.80
$37.53
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Name
Inhibrx Biosciences Inc
Sector
Industry
Phone
(858) 795-4220
Address
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
33.58 | 470.27M | 1.80M | 1.76B | -149.23M | 118.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.62 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.68 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
552.20 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
809.14 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.45 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-23-24 | Initiated | JMP Securities | Mkt Perform |
| Jan-23-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Mar-16-22 | Initiated | SMBC Nikko | Outperform |
| Sep-21-21 | Initiated | JMP Securities | Mkt Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Evercore ISI | Outperform |
View All
Inhibrx Biosciences Inc Stock (INBX) Latest News
How to recover losses in Inhibrx Biosciences Inc. stock2025 Fundamental Recap & Low Risk Growth Stock Ideas - newser.com
Regression analysis insights on Inhibrx Biosciences Inc. performance2025 Breakouts & Breakdowns & Consistent Income Trade Ideas - newser.com
Will Inhibrx Biosciences Inc. benefit from macro trendsJuly 2025 Summary & Free Technical Confirmation Trade Alerts - newser.com
What to expect from Inhibrx Biosciences Inc. in the next 30 days2025 Major Catalysts & Community Verified Swing Trade Signals - newser.com
Owning 45% shares,institutional owners seem interested in Inhibrx Biosciences, Inc. (NASDAQ:INBX), - Yahoo Finance
Insider Selling: Inhibrx Biosciences (NASDAQ:INBX) Major Shareholder Sells 350,000 Shares of Stock - MarketBeat
Automated trading signals detected on Inhibrx Biosciences Inc.Weekly Trend Summary & High Return Trade Opportunity Guides - newser.com
Market reaction to Inhibrx Biosciences Inc.’s recent newsOil Prices & Growth Focused Stock Reports - newser.com
Inhibrx Biosciences Inc. recovery potential after sell offWeekly Profit Analysis & Reliable Volume Spike Alerts - newser.com
How to interpret RSI for Inhibrx Biosciences Inc. stock2025 Investor Takeaways & AI Enhanced Trading Signals - newser.com
Can Inhibrx Biosciences Inc. stock beat analyst upgradesEarnings Overview Summary & Safe Entry Trade Signal Reports - newser.com
Can Inhibrx Biosciences Inc. stock resist market sell offs2025 Performance Recap & Community Trade Idea Sharing - newser.com
Intraday pattern recognizer results for Inhibrx Biosciences Inc.2025 Dividend Review & Real-Time Market Trend Scan - newser.com
Is now a turning point for Inhibrx Biosciences Inc.2025 Earnings Surprises & Verified Technical Trade Signals - newser.com
Inhibrx Biosciences (NASDAQ:INBX) Given Sell (D) Rating at Weiss Ratings - MarketBeat
Custom watchlist performance reports with Inhibrx Biosciences Inc.Earnings Trend Report & Long-Term Growth Portfolio Plans - newser.com
What drives Inhibrx Biosciences Inc stock priceValue Stock Picks & Minimal Investment Trading Plans - earlytimes.in
Technical signs of recovery in Inhibrx Biosciences Inc.Quarterly Investment Review & High Conviction Investment Ideas - newser.com
What analysts say about Inhibrx Biosciences Inc stockVolatility Index Analysis & Achieve Consistent Profits - earlytimes.in
Leading vs lagging indicators on Inhibrx Biosciences Inc. performanceForecast Cut & AI Enhanced Trade Execution Alerts - newser.com
Inhibrx Biosciences Inc. stock retracement – recovery analysisGap Down & Long-Term Safe Investment Plans - newser.com
What technical models suggest about Inhibrx Biosciences Inc.’s comeback2025 Macro Impact & Short-Term High Return Strategies - newser.com
Inhibrx Biosciences (NASDAQ:INBX) Hits New 52-Week HighWhat's Next? - MarketBeat
Published on: 2025-09-30 05:59:24 - newser.com
Using Ichimoku Cloud for Inhibrx Biosciences Inc. technicalsCEO Change & Entry Point Strategy Guides - newser.com
Inhibrx Biosciences Inc Stock (INBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Inhibrx Biosciences Inc Stock (INBX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kayyem Jon Faiz | Director |
Nov 19 '24 |
Buy |
14.23 |
69,686 |
991,416 |
51,093 |
| Kayyem Jon Faiz | Director |
Nov 20 '24 |
Buy |
14.19 |
37,500 |
532,204 |
69,843 |
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):